RxDoctor Payments Data

Lynsey Schlotzer, MD

Family Medicine · Ponte Vedra, FLNPI 1700025012

Payments from drug & device makers

$518in general payments, 2019–2025

Across 16 payments — averaging $32.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$137
  • AstraZeneca$99
  • Dexcom, Inc.$90
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • Coloplast$29
  • Nalpropion Pharmaceuticals LLC$26
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$195,793
Medicare patients
429
Services billed
2,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$86,357
MounjaroTirzepatide52$71,868
MyrbetriqMirabegron30$27,315
EliquisApixaban16$22,116
JardianceEmpagliflozin12$21,465
SynthroidLevothyroxine Sodium108$7,472
Breo ElliptaFluticasone/Vilanterol11$5,088
Levothyroxine Sodium280$3,770
Atorvastatin Calcium335$2,887
Rosuvastatin Calcium177$2,250
Losartan Potassium170$1,926
Amlodipine Besylate256$1,899
Estradiol18$1,701
Valsartan58$1,328
ValacyclovirValacyclovir Hcl40$1,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$86,35776 claims
Lilly USA, LLCMounjaro$25$71,86852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ponte Vedra

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →